Nevro Corp. (NYSE:NVRO) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP reduced its position in Nevro Corp. (NYSE:NVRO) by 21.5% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 132,932 shares of the medical equipment provider’s stock after selling 36,442 shares during the quarter. Dimensional Fund Advisors LP owned about 0.35% of Nevro worth $495,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of NVRO. Prudential Financial Inc. increased its stake in Nevro by 243.4% in the 4th quarter. Prudential Financial Inc. now owns 195,680 shares of the medical equipment provider’s stock valued at $728,000 after buying an additional 138,700 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Nevro during the 4th quarter worth $287,000. Norden Group LLC purchased a new stake in shares of Nevro during the 4th quarter worth $84,000. Townsquare Capital LLC purchased a new stake in shares of Nevro during the 4th quarter worth $84,000. Finally, Sei Investments Co. purchased a new stake in shares of Nevro during the 4th quarter worth $77,000. 95.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have commented on NVRO shares. Canaccord Genuity Group boosted their target price on shares of Nevro from $4.00 to $5.85 and gave the stock a “hold” rating in a research report on Friday, February 7th. Jefferies Financial Group upgraded shares of Nevro from an “underperform” rating to a “hold” rating and boosted their target price for the stock from $4.50 to $5.85 in a research report on Monday, February 10th. Piper Sandler upgraded shares of Nevro from a “neutral” rating to an “overweight” rating and decreased their target price for the stock from $6.00 to $5.85 in a research report on Friday, February 7th. Finally, StockNews.com started coverage on shares of Nevro in a research report on Friday, May 9th. They set a “hold” rating on the stock. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and one has given a buy rating to the stock. According to MarketBeat, Nevro currently has a consensus rating of “Hold” and an average target price of $5.36.

Nevro Stock Performance

NVRO stock opened at $5.85 on Friday. The stock has a market capitalization of $224.32 million, a price-to-earnings ratio of -3.09 and a beta of 0.81. The company has a debt-to-equity ratio of 0.67, a quick ratio of 3.76 and a current ratio of 5.02. Nevro Corp. has a 1 year low of $3.17 and a 1 year high of $11.65. The stock’s fifty day moving average is $5.83 and its two-hundred day moving average is $5.13.

Nevro (NYSE:NVRO) last issued its quarterly earnings results on Tuesday, March 4th. The medical equipment provider reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.15. The company had revenue of $105.55 million for the quarter, compared to analyst estimates of $102.61 million. Nevro had a negative return on equity of 23.52% and a negative net margin of 16.54%. On average, research analysts predict that Nevro Corp. will post -2.44 EPS for the current year.

About Nevro

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.